| abstract |
The present invention relates to an in vitro method for predicting a response of a patient having a neurodevelopmental, neurological or neuropsychiatric condition, if treated with a compound that targets a glutamate-inducing pathway, comprising the following steps: i) determining a sample of the patient a protein concentration of one, two, three, four, five or six members of the complement factor H family, or a mixture or combination thereof, ii) the concentration of the protein determined in step i) Comparison of the protein concentration values of 1, 2, 3, 4, 5 or 6 members of the complement factor H family in patients with neurodevelopmental, neurological or neuropsychiatric disorders, iii) In patients with neurodevelopmental, neurological or neuropsychiatric disorders, a higher concentration of protein from one, two, three, four, five or six members of the complement factor H family indicates that the patient will Clinical benefit is obtained from this treatment, and iv) this treatment is selected for patients with neurodevelopmental, neurological or neuropsychiatric disorders. |